Antirheumatic Agents

"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that are used to treat RHEUMATOID ARTHRITIS.

Descriptor ID	D018501
MeSH Number(s)	D27.505.954.329
Concept/Terms	Antirheumatic Agents Antirheumatic Agents Anti-Rheumatic Drugs Anti Rheumatic Drugs Antirheumatic Drugs Anti-Rheumatic Agents Anti Rheumatic Agents Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease-Modifying Antirheumatic Drugs, Disease Modifying DMARD Disease-Modifying, Antirheumatic Second-Line Drugs Disease Modifying, Antirheumatic Second Line Drugs Antirheumatic Disease-Modifying Second-Line Drugs Antirheumatic Disease Modifying Second Line Drugs Disease-Modifying Antirheumatic Drugs Disease Modifying Antirheumatic Drugs Anti-Rheumatic Agents, Non-Steroidal Anti-Rheumatic Agents, Non-Steroidal Anti Rheumatic Agents, Non Steroidal Non-Steroidal Anti-Rheumatic Agents

Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antirheumatic Agents [D27.505.954.329]

Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.

Bar chart showing 167 publications over 25 distinct years, with a maximum of 15 publications in 2015 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	1	0	1
2002	1	0	1
2003	0	2	2
2005	1	0	1
2006	2	1	3
2007	3	1	4
2008	3	2	5
2009	6	1	7
2010	3	2	5
2011	3	3	6
2012	9	3	12
2013	13	0	13
2014	5	2	7
2015	13	2	15
2016	12	1	13
2017	11	1	12
2018	9	1	10
2019	9	6	15
2020	6	2	8
2021	3	1	4
2022	6	0	6
2023	6	0	6
2024	9	0	9
2025	1	0	1

Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.

Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials. 2025 Mar 19; 26(1):96.

View in: PubMed
Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.

View in: PubMed
Baker JF, Reed G, Mikuls TR, Thiele GM, Pappas DA, Charles-Schoeman C, Guma M, Harrold LR, Curtis JR, Kremer JM. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2025 Mar; 77(3):263-271.

View in: PubMed
Huang YC, Lee NY, Weng MY. Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor. J Microbiol Immunol Infect. 2025 Feb; 58(1):112-119.

View in: PubMed
Pappas DA, Reed G, Kane K, Curtis JR, Charles-Schoeman C, Giles JT, Kremer JM. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients. Semin Arthritis Rheum. 2024 Oct; 68:152504.

View in: PubMed
Kay J, Nikolov NP, Weisman MH. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022. Arthritis Rheumatol. 2024 Sep; 76(9):1323-1333.

View in: PubMed
Shridharmurthy D, Lapane KL, Baek J, Nunes AP, Weisman MH, Kay J, Liu SH. Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2024 08; 76(8):1149-1161.

View in: PubMed
Aripova N, Kremer JM, Pappas DA, Reed G, England BR, Robinson BH, Curtis JR, Thiele GM, Mikuls TR. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford). 2024 02 01; 63(2):542-550.

View in: PubMed
Mease PJ, Blachley T, Malatestinic WN, Harrold LR, Dube B, Lisse JR, Bolce RJ, Hunter TM. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry. Curr Med Res Opin. 2024 02; 40(2):315-323.

View in: PubMed
Harrold LR, Wittstock K, Kelly S, Han X, Zhuo J, Schrader A, Middaugh N, Moore PC, Khaychuk V. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive. Adv Rheumatol. 2024 01 19; 64(1):10.

View in: PubMed

People

Explore

Similar Concepts

Top Journals